Abstract: The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (AAV vector) comprising a first gene encoding a myocardin-related transcription factor A (MRTF-A). The invention further also relates to a pharmaceutical composition comprising an AAV vector of the invention and a pharmaceutically acceptable carrier. Methods for preparing the vector of the invention are also disclosed.

Abstract: A method of treating an ischemic heart disease in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of Agrin in an anterograde intracoronary manner, thereby treating the ischemic heart disease in the subject.

Abstract: The present invention relates to compositions and methods for increasing tolerance to abiotic stress and/or for reducing the consequence of abiotic stress in a plant and/or part thereof. In some aspects, the method comprises contacting a plant and/or part thereof with a first composition comprising one or more of aminoguanidine, L-nitroarginine, L-nitroarginine methyl ester, 2,2?-bipyridine, 4-methylpyrazole, 8-hydroxyquiniline, caprylic acid, pyrazole, naringenin, kaempferol, quercetin, dodecanoic acid, and/or undecanoic acid, and/or a salt thereof; and a second composition comprising at least one dicarboxylic acid and/or a salt thereof.

Abstract: The present invention relates a vector system and a vector system for use in a method of treating a disease, each comprising a first vector and a second vector. The present invention further relates to the first vector, the second vector and a combination of the first vector and the second vector. In addition, the present invention relates to a pharmaceutical composition comprising the vector system of the invention or the combination of the invention.

Abstract: The present invention relates to compositions and methods for increasing tolerance to abiotic stress and/or for reducing the consequence of abiotic stress in a plant and/or part thereof. In some aspects, the method comprises contacting a plant and/or part thereof with a first composition comprising one or more of aminoguanidine, L-nitroarginine, L-nitroarginine methyl ester, 2,2?-bipyridine, 4-methylpyrazole, 8-hydroxyquiniline, caprylic acid, pyrazole, naringenin, kaempferol, quercetin, dodecanoic acid, and/or undecanoic acid, and/or a salt thereof; and a second composition comprising at least one dicarboxylic acid and/or a salt thereof.

Abstract: A method of treating an ischemic heart disease in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of Agrin in an anterograde intracoronary manner, thereby treating the ischemic heart disease in the subject.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (AAV vector) comprising a first gene encoding a myocardin-related transcription factor A (MRTF-A). The invention further also relates to a pharmaceutical composition comprising an AAV vector of the invention and a pharmaceutically acceptable carrier. Methods for preparing the vector of the invention are also disclosed.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The present invention provides a method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof comprising contacting a plant or part thereof with a composition comprising an effective amount of dicarboxylic acid or derivative thereof.

Abstract: The present application is directed to methods and compositions for improving growth or yield of plants by reducing stress from abiotic factors without adversely affecting photosynthesis. In one embodiment, the compositions include particulate material and one or more plant growth regulating compounds such as non-gaseous plant hormones, amino acids and amino acid derivatives, and terpenes, and mixtures thereof. The composition is applied to at least part of the surface of the plant, forming a film on the plant. The effects of abiotic factors such as heat, cold, light, and water stress may be reduced or eliminated after application of the composition, and growth or yield may be increased while photosynthesis is not adversely affected.